This is a summary of the European Public Assessment Report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.
If you need more information about your medical condition or your treatment, read the Package Leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis for the CHMP recommendations, read the Scientific Discussion (also part of the EPAR).
- What is Clopidogrel Krka?
Clopidogrel Krka is a medicine that contains the active substance clopidogrel. It is available as pink, round tablets (75 mg).
Clopidogrel Krka is a ‘generic medicine’. This means that Clopidogrel Krka is similar to a ‘reference medicine’ already authorised in the European Union (EU) called Plavix.
- What is Clopidogrel Krka used for?
Clopidogrel Krka is used in adults to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries). Clopidogrel Krka can be given to the following groups of patients:
- patients who have recently had a myocardial infarction (heart attack). Clopidogrel Krka can be started between a few days and 35 days after the attack;
- patients who have had a recent ischaemic stroke (stroke caused by failure of the blood supply to part of the brain). Clopidogrel Krka can be started between seven days and six months after the stroke;
- patients with peripheral arterial disease (problems with blood flow in the arteries).
The medicine can only be obtained with a prescription.
- How is Clopidogrel Krka used?
The standard dose of Clopidogrel Krka is one 75 mg tablet once a day, taken with or without food.
- How does Clopidogrel Krka work?
The active substance in Clopidogrel Krka, clopidogrel, is an inhibitor of platelet aggregation. This means that it helps to prevent blood clots from forming. When the blood clots, this is due to special cells in the blood called platelets aggregating (sticking together). Clopidogrel stops the platelets aggregating by blocking a substance called ADP from attaching to a special receptor on their surface. This stops the platelets becoming ‘sticky’, reducing the risk of a blood clot forming and helping to prevent another heart attack or stroke.
- How has Clopidogrel Krka been studied?
Because Clopidogrel Krka is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine, Plavix. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.
- What are the benefit and risk of Clopidogrel Krka?
Because Clopidogrel Krka is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.
- Why has Clopidogrel Krka been approved?
The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Clopidogrel Krka has been shown to have comparable quality and to be bioequivalent to Plavix. Therefore, the CHMP’s view was that, as for Plavix, the benefit outweighs the identified risk. The Committee recommended that Clopidogrel Krka be given marketing authorisation.
- Other information about Clopidogrel Krka
The European Commission granted a marketing authorisation valid throughout the EU for Clopidogrel Krka to Krka, d.d., Novo mesto on 23 September 2009.
This EPAR was last updated on 20/01/2016 .
08/12/2015 Clopidogrel Krka -EMEA/H/C/001056 -IB/0027/G
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:
- Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
Changes since initial authorisation of medicine
|Name||Language||First published||Last updated|
|Clopidogrel Krka : EPAR - Procedural steps taken and scientific information after authorisation||SV = svenska||15/12/2009||20/01/2016|
Initial marketing-authorisation documents
|Name||Language||First published||Last updated|
|Clopidogrel Krka : EPAR - Public assessment report||SV = svenska||20/10/2009|
|Committee for medicinal products for human use summary of positive opinion for Clopidogrel Krka||SV = svenska||25/06/2009|